Literature DB >> 16924371

Non-angiogenic functions of VEGF in breast cancer.

Arthur M Mercurio1, Elizabeth A Lipscomb, Robin E Bachelder.   

Abstract

This review advances the hypothesis that the function of vascular endothelial growth factor (VEGF) in breast cancer is not limited to angiogenesis, and that VEGF signaling in breast carcinoma cells is important for the ability of these cells to evade apoptosis and progress towards invasive and metastatic disease. In other terms, VEGF signaling provides a selective advantage for the survival and dissemination of breast carcinoma cells that may be independent of angiogenesis. The key component of this hypothesis is that breast carcinoma cells express specific VEGF receptors and that these receptors respond to autocrine VEGF, resulting in the activation of signaling pathways that impede apoptosis and promote cell migration. A related hypothesis, which is developed in this review, is that the alpha6beta4 integrin, which has been implicated in the survival and motility of breast cancer cells, can stimulate the translation of VEGF mRNA and, consequently, autocrine VEGF signaling. These findings imply that VEGF and VEGF receptor-based therapeutics, in addition to targeting angiogenesis, may also target tumor cells directly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16924371     DOI: 10.1007/s10911-006-9001-9

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  60 in total

1.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.

Authors:  Valerie M Weaver; Sophie Lelièvre; Johnathon N Lakins; Micah A Chrenek; Jonathan C R Jones; Filippo Giancotti; Zena Werb; Mina J Bissell
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop.

Authors:  Z von Marschall; T Cramer; M Höcker; R Burde; T Plath; M Schirner; R Heidenreich; G Breier; E O Riecken; B Wiedenmann; S Rosewicz
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

4.  Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates.

Authors:  L Tamagnone; S Artigiani; H Chen; Z He; G I Ming; H Song; A Chedotal; M L Winberg; C S Goodman; M Poo; M Tessier-Lavigne; P M Comoglio
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

5.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

6.  Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

Authors:  Lisa Rydén; Karin Jirström; Pär-Ola Bendahl; Mårten Fernö; Bo Nordenskjöld; Olle Stål; Sten Thorstenson; Per-Ebbe Jönsson; Göran Landberg
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

Review 7.  Epithelial-mesenchymal transitions: twist in development and metastasis.

Authors:  Yibin Kang; Joan Massagué
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

8.  Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.

Authors:  Emely Castro-Rivera; Sophia Ran; Philip Thorpe; John D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

Review 9.  Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.

Authors:  George W Sledge
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

10.  Integrin beta4 signaling promotes tumor angiogenesis.

Authors:  Sotiris N Nikolopoulos; Pamela Blaikie; Toshiaki Yoshioka; Wenjun Guo; Filippo G Giancotti
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

View more
  27 in total

1.  Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.

Authors:  Christine F O'Neill; Sumithra Urs; Christina Cinelli; Alexis Lincoln; Robert J Nadeau; Ruth León; Jessica Toher; Carla Mouta-Bellum; Robert E Friesel; Lucy Liaw
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

2.  Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast.

Authors:  Angélica Morales; Sumiko Morimoto; Felipe Vilchis; Natsuko Taniyama; Claudia J Bautista; Carlos Robles; Enrique Bargalló
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

3.  Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression.

Authors:  Takaaki Fujii; Reina Yajima; Hironori Tatsuki; Katuya Oosone; Hiroyuki Kuwano
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-10-01       Impact factor: 2.416

4.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

Review 5.  Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion.

Authors:  Martine Perrot-Applanat; Melanie Di Benedetto
Journal:  Cell Adh Migr       Date:  2012-11-01       Impact factor: 3.405

6.  North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.

Authors:  E A Perez; D W Hillman; T Dentchev; N A Le-Lindqwister; L H Geeraerts; T R Fitch; H Liu; D L Graham; S P Kahanic; H M Gross; T A Patel; F M Palmieri; A C Dueck
Journal:  Ann Oncol       Date:  2009-11-09       Impact factor: 32.976

7.  Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels.

Authors:  Marie-Astrid Hervé; Hélène Buteau-Lozano; Roger Vassy; Ivan Bieche; Guillaume Velasco; Marika Pla; Gérard Perret; Samia Mourah; Martine Perrot-Applanat
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

8.  Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

Authors:  Lisa D Volk; Michael J Flister; Christopher M Bivens; Alan Stutzman; Neil Desai; Vuong Trieu; Sophia Ran
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

9.  The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts.

Authors:  Davide Visigalli; Daniela Palmieri; Antonella Strangio; Simonetta Astigiano; Ottavia Barbieri; Gianluigi Casartelli; Antonio Zicca; Paola Manduca
Journal:  BMC Cancer       Date:  2009-02-18       Impact factor: 4.430

10.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Authors:  Shumin Zhang; Haiyen E Zhau; Adeboye O Osunkoya; Shareen Iqbal; Xiaojian Yang; Songqing Fan; Zhengjia Chen; Ruoxiang Wang; Fray F Marshall; Leland W K Chung; Daqing Wu
Journal:  Mol Cancer       Date:  2010-01-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.